News | December 30, 2025
Harbour BioMed teams up with Lannacheng to advance next-generation cancer therapies
Harbour BioMed brings advanced antibody discovery platforms to the table
Harbour BioMed brings advanced antibody discovery platforms to the table
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines
Subscribe To Our Newsletter & Stay Updated
